FOLH1 and neoplasm: Nonetheless, the results indicate that all tumor-bearing groups exhibited elevated globulin levels compared to the non-tumor groups treated with [225Ac]Ac-PSMA-617 and [177Lu]Lu-PSMA-617, suggesting that the increased levels are attributable to the presence of tumors rather than toxicity from radioligand therapy.